Successful fiscal year 2023, with a year-on-year increase in revenues of 9% to EUR 899m supported by increased share of revenue from strong-margin high-value solutions
Strong EBITDA increase of 9% to EUR 239m leads to an EBITDA margin of 26.6%
Full set of FY 2023 financial results to be published on January 26, 2024
SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, closed its fiscal year 2023¹ with revenues of EUR 899m at the upper end of its guidance. Compared to EUR 821m in FY 2022, this represents a strong increase of 9%, taking into account the effects of customers’ temporary destocking in the core vials product category during the year. The company’s EBITDA increased in line with revenue to EUR 239m (+9% yoy), enabling SCHOTT Pharma to maintain its high EBITDA margin of 26.6%. The strong growth was enabled by the expansion of SCHOTT Pharma’s production capacities, especially for drug delivery systems and the new production lines for prefillable polymer syringes in Müllheim, Germany. This key milestone was also a key contributor to the share of revenue from strong-margin high-value solutions increasing by 9 percentage points to 48%, which was better than expected.
“We are very pleased that we were able to fully deliver on our promises and meet our growth targets that we set out during our recent IPO. Our strong growth and high level of profitability not only continue to demonstrate our attractive financial profile, but also confirm our strategic focus on pharma trends and the fast-growing market for high-value solutions. For those reasons, we are confident about both the coming financial year and our mid-term targets”, said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. The strong performance of high-value solutions (HVS) drove impressive overall growth despite the effects of underutilization in the core vials product category from customer destocking in the second half of the financial year.
With its products, SCHOTT Pharma serves some of the most important and exciting pharma trends, such as GLP-1, homecare and mRNA, that will continue to serve as growth drivers. The company continuously develops solutions for new drug categories to ensure their safe storage and administration to patients all over the world.
As of December 18, 2023, SCHOTT Pharma was included in the SDAX, joining the DAX family for the first time.
SCHOTT Pharma will publish its 2023 annual report including the non-financial report on January 26, 2024.
20.12.2023, SCHOTT
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.